Alithia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.44 M
as on 12-12-2024
- Paid Up Capital ₹ 1.44 M
as on 12-12-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 27.00 Cr
as on 12-12-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 980.49%
(FY 2023)
About Alithia Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.44 M and a paid-up capital of Rs 1.44 M.
The company currently has active open charges totaling ₹27.00 Cr.
Jagadeesh Rangisetty, Manikreddy Pullagurla, and Mundla Vishnu serve as directors at the Company.
- CIN/LLPIN
U24290TG2021PTC152799
- Company No.
152799
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alithia Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mundla Vishnu  | Director | 05-Jul-2021 | Current |
| Jagadeesh Rangisetty | Director | 05-Jul-2021 | Current |
| Manikreddy Pullagurla | Director | 05-Jul-2021 | Current |
Financial Performance and Corporate Structure Insights of Alithia Pharmaceuticals.
Alithia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Alithia Pharmaceuticals?
In 2023, Alithia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Azico Biophore India Private LimitedActive 16 years 1 monthJagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
Leiutis Pharmaceuticals LlpActive 3 years 7 monthsJagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Jul 2022 | ₹27.00 Cr | Open |
How Many Employees Work at Alithia Pharmaceuticals?
Unlock and access historical data on people associated with Alithia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alithia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alithia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
